{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:27:00Z","timestamp":1786987620834,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor, has demonstrated efficacy and safety in phase III clinical trials for moderate-to-severe plaque psoriasis. However, real-world evidence remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of deucravacitinib in adult patients with moderate-to-severe plaque psoriasis treated in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, single-centre, real-world observational study. Consecutive adult patients with \u00admoderate-to-severe plaque psoriasis who initiated deucravacitinib between December 2024 and December 2025 were retrospectively identified. At each follow-up Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), body \u00adsurface area (BSA), numeric rating scale (NRS) pruritus. In addition, \u2265 75% improvement in PASI (PASI 75), \u2265 90% improvement in PASI (PASI 90) and 100% improvement in PASI (PASI 100) response rates were also evaluated. Safety was assessed through adverse event reporting and routine laboratory monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 46 patients completed the 24-week follow-up and were included in the study. Mean PASI decreased from 12.5 (SD 3.1) at baseline to 3.2 (SD 2.1) at week 24 (P &amp;lt; 0.001) and mean BSA decreased from 18.0% (SD 6.5%) to 5.0% (SD 3.6) (P &amp;lt; 0.001). NRS pruritus and DLQI also improved significantly over time (both P &amp;lt; 0.001). Of the 46 patients, PASI 75 was achieved by 70% (n = 32) at week 24, and PASI 90 and PASI 100 were achieved by 54% (n = 25) and 33% (n = 15), respectively. No serious adverse events or clinically relevant laboratory abnormalities were observed. Acne was the most frequent adverse event, occurring in 4 of 46 patients (9%), and was mild in all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favourable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag187","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:41:14Z","timestamp":1776944474000},"page":"1654-1660","source":"Crossref","is-referenced-by-count":0,"title":["Deucravacitinib in moderate-to-severe plaque psoriasis: a real-world study of effectiveness and safety in clinical practice"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Mozzillo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cordedda","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-9163","authenticated-orcid":false,"given":"Elisa","family":"Camela","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zanchini","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Colasanti","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Zagaria","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Section of Dermatology, Ospedale del Mare , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2026081712355309200_llag187-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026081712355309200_llag187-B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"A first-in-human study of deucravacitinib, a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2026081712355309200_llag187-B3","doi-asserted-by":"crossref","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026081712355309200_llag187-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026081712355309200_llag187-B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026081712355309200_llag187-B6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of deucravacitinib in moderate to severe plaque psoriasis for up to 3\u2005years: an open-label extension of randomized clinical trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026081712355309200_llag187-B7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14740338.2024.2351462","article-title":"Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation","volume":"23","author":"Potestio","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2026081712355309200_llag187-B8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026081712355309200_llag187-B9","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026081712355309200_llag187-B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ced\/llae312","article-title":"Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: a 24-week real-world study","volume":"50","author":"Hagino","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026081712355309200_llag187-B11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026081712355309200_llag187-B12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026081712355309200_llag187-B13","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081712355309200_llag187-B14","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s13555-024-01262-5","article-title":"Pharmacodynamic response to deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in a global, phase 2, randomized, double-blind, placebo-controlled psoriasis trial","volume":"14","author":"Catlett","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026081712355309200_llag187-B15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the phase III POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712355309200_llag187-B16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety analysis through 52 weeks from the phase III POETYK PSO-1 and PSO-2 trials","volume":"38","author":"Strober","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712355309200_llag187-B17","first-page":"653","article-title":"A real-world study on the effectiveness and safety of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis in China","volume":"54","author":"Zhang","year":"2025","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"2026081712355309200_llag187-B18","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ced\/llae530","article-title":"Long-term effectiveness and safety of deucravacitinib for psoriasis: a 52-week real-world study of genital, scalp and nail lesions","volume":"50","author":"Hagino","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026081712355309200_llag187-B19","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s13555-024-01224-x","article-title":"Deucravacitinib improves patient-reported outcomes in patients with moderate to severe psoriasis: results from the phase 3 randomized POETYK PSO-1 and PSO-2 trials","volume":"14","author":"Armstrong","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026081712355309200_llag187-B20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","article-title":"Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data","volume":"71","author":"Ruggiero","year":"2023","journal-title":"Immunol Res"},{"key":"2026081712355309200_llag187-B21","doi-asserted-by":"crossref","first-page":"e15214","DOI":"10.1111\/dth.15214","article-title":"Real world practice indirect comparison between guselkumab and risankizumab: results from an Italian retrospective study","volume":"35","author":"Ruggiero","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026081712355309200_llag187-B22","first-page":"41","article-title":"The impact of genital psoriasis on quality of life: a systematic review","volume":"8","author":"Yang","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"2026081712355309200_llag187-B23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CCID.S189000","article-title":"Inverse psoriasis: from diagnosis to current treatment options","volume":"12","author":"Micali","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026081712355309200_llag187-B24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/09546630701341949","article-title":"Psoriasis of the face and flexures","volume":"18","author":"van de Kerkhof","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"2026081712355309200_llag187-B25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.14227","article-title":"Adult genital psoriasis: an updated review for clinicians","volume":"65","author":"Wu","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026081712355309200_llag187-B26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/24755303231160683","article-title":"Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities","volume":"8","author":"Blauvelt","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2026081712355309200_llag187-B27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdin.2025.09.022","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with moderate to severe scalp psoriasis: efficacy and safety results through week 16 in a phase 3b\/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)","volume":"25","author":"Duffin","year":"2025","journal-title":"JAAD Int"},{"key":"2026081712355309200_llag187-B28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/1346-8138.17744","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with plaque psoriasis: in-depth analysis of efficacy and safety in the phase 3 POETYK PSO-4 trial","volume":"52","author":"Okubo","year":"2025","journal-title":"J Dermatol"},{"key":"2026081712355309200_llag187-B29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/jdv.12761","article-title":"Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study","volume":"29","author":"Mrowietz","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026081712355309200_llag187-B30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7525-7-62","article-title":"The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups","volume":"7","author":"Globe","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2026081712355309200_llag187-B31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ajd.14425","article-title":"Acneiform eruption secondary to deucravacitinib: a case series and review of the literature","volume":"66","author":"Tran","year":"2025","journal-title":"Australas J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag187\/68160632\/llag187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1654\/68160632\/llag187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/9\/1654\/68160632\/llag187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:35:59Z","timestamp":1786984559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/9\/1654\/8662642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,4,25]]},"published-print":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag187","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,4,25]]}}}